Ballicules.com

Armodafinil

NUVIGIL

What it isDopamine-reuptake-inhibiting wake-promoter; narcolepsy, sleep-apnea sleepiness, and shift-work disorder.

Why this oneAs modafinil's R-enantiomer, it sustains wakefulness later in the day from morning administration.

What limits itCYP3A4 induction can compromise hormonal contraception. Serious rash, insomnia, and misuse risk also matter.

FDA-approved for

Off-label

FDA label

FDA dosingPopulationStartTargetMax
Obstructive sleep apnea (excessive sleepiness)adults150-250 mg QD (morning)150-250 mg QD250 mg QD
Narcolepsyadults150-250 mg QD (morning)150-250 mg QD250 mg QD
Shift work disorderadults150 mg QD (~1 h before shift)150 mg QD150 mg QD

Renal Undefined

Hepatic Severe hepatic impairment: reduce dose.

Instructions

Cautions

Adverse reactions

Pregnancy Insufficient data; IUGR and spontaneous abortion reported; may cause fetal harm (animal data).

Lactation Undefined

NO BOXED WARNINGS

Principal riskIt induces CYP3A4 enough to fail oral contraceptives

Cost, est. cash$10–$300/month

Generic entry2012

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilitySerious rash, psychiatric activation and CYP-mediated interactions; misuse potential is present.

Mechanism of action: Armodafinil ballicule

Armodafinil ballicule: receptor binding, kinetics and half-life diagram

Open Armodafinil in the interactive console ↗

Memory aids: mascots and interaction avatars

Armodafinil NUVIGIL mascot mnemonic cartoon
“Armored Daffodil”
Armodafinil CYP3A4 inducer avatar
CYP3A4 inducer (moderate)

Open Armodafinil in the interactive console ↗